随着MSCI多个指数成份股调整，相关的指数基金也将随之调仓，新纳入的企业将得到更多的资金配 置；而被剔除的企业将会被相关指数基金被动卖出。资金流向上，根据指数调整的历史经验来看，被动 型资金为了尽可能地减少对于指数的追踪误差，通常会选在最后一天调仓，因此往往也会看到权重变动 较大的个股成交"异常"放大，特别是在尾盘。 全球知名指数公司MSCI此前宣布了2025年11月份指数审核结果，此次调整将于2025年11月24日收盘后 正式生效。在MSCI的系列指数中，涉及A股的包括MSCI中国指数、MSCI中国A股在岸指数以及MSCI 中国全股票指数。其中最值得关注的是MSCI中国指数。MSCI中国指数被嵌套进MSCI新兴市场指数， 因此股票进入MSCI中国指数，便意味着进入了MSCI全球标准指数系列，从而获得被动资金跟踪。 MSCI中国指数本次新增26只标的，包括多只资源股，以及半导体、高端制造等科技类公司。新增个股 包括9只港股：紫金黄金国际(02259)、广发证券(01776)、赣锋锂业(01772)、中国有色矿业(01258)、中 国黄金国际(02099)、荣昌生物(09995)、东风集团(00489)、优必选 ...

（原标题：港股概念追踪 | MSCI中国指数调整将生效 关注个股尾盘异动 外资持续加码中国优质资产(附概念股)） 智通财经APP获悉，全球知名指数公司MSCI此前宣布了2025年11月份指数审核结果，此次调整将于2025年11月24日收盘后正式生效。在MSCI的 系列指数中，涉及A股的包括MSCI中国指数、MSCI中国A股在岸指数以及MSCI中国全股票指数。其中最值得关注的是MSCI中国指数。MSCI中 国指数被嵌套进MSCI新兴市场指数，因此股票进入MSCI中国指数，便意味着进入了MSCI全球标准指数系列，从而获得被动资金跟踪。 MSCI中国指数本次新增26只标的，包括多只资源股，以及半导体、高端制造等科技类公司。新增个股包括9只港股：紫金黄金国际(02259)、广发 证券(01776)、赣锋锂业(01772)、中国有色矿业(01258)、中国黄金国际(02099)、荣昌生物(09995)、东风集团(00489)、优必选(09880)、晶泰控股 (02228)。以及华虹公司、生益电子、英维克、长盈精密、江波龙、中材科技等17只A股。 同时，MSCI中国指数剔除了20只中国股票，其中包括4只港股：北控水务集团 ...

Core Viewpoint - Jingtai Holdings (02228) has successfully developed and validated two innovative topical active ingredients for hair loss prevention and growth, leveraging its industry-leading AI molecular discovery platform, marking its entry into the consumer health sector [1] Group 1: Product Development - The two active ingredients developed are small molecule Remeanagen (XTP-118) and peptide AquaKine (XTP-016), both of which have successfully passed the INCI registration in the United States [1] - The combined formulation product Groland has also received FDA registration, indicating regulatory approval for market entry [1] Group 2: Strategic Partnerships - Jingtai's wholly-owned subsidiary Ailux has entered into a multi-target strategic cooperation and platform licensing agreement with Eli Lilly, with a total agreement value of up to $345 million, including several million dollars in upfront payments and milestone payments [1] - This partnership aims to accelerate the discovery and development of bispecific antibodies across multiple therapeutic areas, utilizing Ailux's proprietary platform and AI antibody research capabilities [1] - This collaboration follows a previous $250 million agreement between Jingtai Technology and Eli Lilly for AI small molecule drug development [1]

Core Viewpoint - Jingtai Holdings (02228) has successfully developed and validated two innovative topical active ingredients for hair loss prevention and growth, leveraging its industry-leading AI molecular discovery platform [1] Group 1: Product Development - The two developed molecules are small molecule Remeanagen (XTP-118) and peptide AquaKine (XTP-016), both of which have successfully passed the INCI registration in the US [1] - The combined formula product Groland has also received FDA registration, marking Jingtai's entry into the promising consumer health sector [1] Group 2: Strategic Partnerships - Jingtai's wholly-owned subsidiary Ailux has entered into a multi-target strategic cooperation and platform licensing agreement with Eli Lilly, with a total agreement value of up to $345 million, including tens of millions in upfront payments and milestone payments [1] - Eli Lilly will utilize Ailux's proprietary platform to accelerate the discovery and development of bispecific antibodies across multiple therapeutic areas, while also leveraging its AI antibody research platform to enhance internal pipeline research [1] - This partnership follows a previous $250 million collaboration between Jingtai Technology and Eli Lilly for AI small molecule drug development earlier in 2023 [1]

Core Viewpoint - Crystal Tech Holdings (02228) has successfully developed and validated two innovative topical active ingredients for hair loss prevention and growth, leveraging its industry-leading AI molecular discovery platform [1] Group 1: Product Development - The two active ingredients, small molecule Remeanagen™ (XTP-118) and peptide AquaKine™ (XTP-016), have shown significant improvements in hair growth and anti-hair loss efficacy, safety, and onset speed compared to existing products [1] - Both molecules have successfully passed the INCI (International Nomenclature of Cosmetic Ingredients) registration in the United States [1] - The combined formulation product, Groland, has received cosmetic registration from the FDA (Food and Drug Administration), marking a significant entry into the consumer health sector [1] Group 2: Strategic Vision - Crystal Tech's new mission statement emphasizes the integration of AI into every new drug and the incorporation of AI molecules into enhancing everyday life [1] - The company aims to tackle major diseases through drug development while also creating consumer-grade molecular products to improve the quality of life for the general public [1]

Core Insights - Jingtai Holdings (02228) has successfully developed and validated two innovative topical active ingredients for hair growth and anti-hair loss: small molecule Remeanagen (XTP-118) and peptide AquaKine (XTP-016) [1] - The combination formula of these two molecules has shown significant superiority in hair growth and anti-hair loss effects, safety, and onset speed compared to existing similar products through rigorous human trials [1] - Both molecules have successfully passed the INCI (International Nomenclature of Cosmetic Ingredients) registration in the United States, and the combination product Groland has received FDA (Food and Drug Administration) cosmetic filing, marking Jingtai's entry into the promising consumer health sector [1] - Jingtai aims to tackle major diseases through drug development while also creating consumer-grade molecular products to enhance the quality of daily life [1] - The new mission statement of Jingtai emphasizes the integration of AI into every new drug and the incorporation of AI molecules into everyone's quality of life [1] Company Developments - The AI molecular discovery platform of Jingtai is focused on developing innovative drug molecules that save lives and creating safe and effective consumer product molecules [1] - The successful validation of the dual active ingredients positions Jingtai as a leader in the consumer health market, leveraging its AI capabilities [1]